Cancer pain relief without the sickness: new hope from an old drug
NCT ID NCT07038551
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether naldemedine, a drug already used for opioid-induced constipation, can also prevent nausea and vomiting when cancer patients start strong painkillers. 120 adults with cancer who were beginning opioid therapy took either naldemedine or a placebo for up to 7 days. The main goal was to see if more patients in the naldemedine group had no vomiting and didn't need extra anti-nausea medication by day 5.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
naldemedine
What this could lead to
If it works, this could offer a new way to prevent nausea and vomiting caused by opioid painkillers in cancer patients, making pain management easier.
What could go wrong
This is a completed Phase 4 trial with 120 participants, so results are available but may not apply to all patients. Naldemedine is already used for constipation, so its effect on nausea is still being confirmed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beppu Medical Center
Beppu, Oita Prefecture, Japan
-
Cancer Institute Hospital of Japanese Fo undation for Cancer Research
Tokyo, Tokyo, Japan
-
Hiroshima Prefectural Hospital
Hiroshima, Hiroshima, Japan
-
Hyogo Prefectural Nishinomiya Hospital
Nishinomiya, Hyōgo, Japan
-
IUHW Narita Hospital
Narita, Chiba, Japan
-
Iizuka Hospital
Iizuka, Fukuoka, Japan
-
Kanagawa Dental University Yokohama Clinic
Yokohama, Kanagawa, Japan
-
Kansai Rosai Hospital
Amagasaki, Hyōgo, Japan
-
Kindai University Nara Hospital
Ikoma, Nara, Japan
-
Kyoto University Hospital
Kyoto, Kyoto, Japan
-
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan
-
National Hospital Organization HIMEJI M edical Center
Himeji, Hyōgo, Japan
-
Niigata Cancer Center Hospital
Niigata, Niigata, Japan
-
Osaka Red Cross Hospital
Osaka, Osaka, Japan
-
Osaki Citizen Hospital
Ōsaki, Miyagi, Japan
-
Showa University Koto Toyosu Hospital
Tokyo, Tokyo, Japan
-
St. Marianna University School of Medicine
Kawasaki, Kanagawa, Japan
-
Toyama University Hospital
Toyama, Toyama, Japan
-
Toyohashi municipal hospital
Toyohashi, Aichi-ken, Japan
-
University of Tsukuba Hospital
Tsukuba, Ibaragi, Japan